If enacted, this bill would introduce new provisions to the Arizona Revised Statutes by appropriating $10 million from the state General Fund for fiscal year 2026 to the Department of Health Services (DHS). This funding is designated for grants aimed at clinical trials or research on midomafetamine as a treatment for Post-Traumatic Stress Disorder (PTSD). The bill specifies that grants can only be awarded to entities that have completed at least one late-stage clinical trial and are currently involved in the FDA drug review process for midomafetamine related to PTSD.

Additionally, the bill includes a provision that exempts this appropriation from lapsing, meaning the allocated funds would not expire at the end of the fiscal year as typically required under current law. This change aims to ensure that the funding remains available for its intended purpose without the risk of being lost due to lapsing provisions. Overall, the bill seeks to enhance research efforts for PTSD treatment through targeted funding and specific eligibility criteria for grant recipients.